 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...119120121122123124125126127128129...132133» |
- Avastin (bevacizumab) / Roche
Enrollment change: Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (clinicaltrials.gov) - Jan 15, 2014
P1, N=281, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=190 --> 281
- Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Jan 15, 2014
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=190 --> 281 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Enrollment closed: RAD001 for Patients With Radioiodine Refractory Thyroid Cancer (clinicaltrials.gov) - Jan 15, 2014
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys (clinicaltrials.gov) - Jan 13, 2014
P2/3, N=50, Active, not recruiting, Sponsor: Matthew Cooper
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- everolimus / Generic mfg., sirolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion: PERFECT: Optimal Stenting Strategy For True Bifurcation Lesions (clinicaltrials.gov) - Jan 13, 2014
P4, N=480, Completed, Sponsor: Seung-Jung Park
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Trial suspension, Metastases: Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer (clinicaltrials.gov) - Jan 13, 2014
P1, N=44, Suspended, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Suspended
- metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment change, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jan 12, 2014
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Suspended N=47 --> 64
- topotecan / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers (clinicaltrials.gov) - Jan 12, 2014
P1, N=10, Completed, Sponsor: Yale University
N=47 --> 64 N=36 --> 10
- |||| everolimus / Generic mfg.
Enrollment open, Combination therapy: PROTECT: Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients (clinicaltrials.gov) - Jan 12, 2014
P4, N=234, Recruiting, Sponsor: Seoul St. Mary's Hospital
N=36 --> 10 Not yet recruiting --> Recruiting
- topotecan / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers (clinicaltrials.gov) - Jan 12, 2014
P1, N=10, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting Recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Enrollment change, Epigenetic controller, Metastases: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) - Jan 8, 2014
P1, N=219, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed N=107 --> 219
- | everolimus / Generic mfg.
New P2 trial, Surgery, Metastases: Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery (clinicaltrials.gov) - Jan 7, 2014
P2, N=150, Not yet recruiting, Sponsor: Eastern Cooperative Oncology Group
- |||| carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 6, 2014
P2, N=69, Completed, Sponsor: SCRI Development Innovations, LLC
N=107 --> 219 Active, not recruiting --> Completed
- ||||| everolimus / Generic mfg.
Biomarker, New P2 trial: PEARL: Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women (clinicaltrials.gov) - Jan 5, 2014
P2, N=130, Not yet recruiting, Sponsor: Jules Bordet Institute
- | New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: MOST plus: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (clinicaltrials.gov) - Jan 5, 2014
P2, N=560, Recruiting, Sponsor: Centre Leon Berard
- everolimus / Generic mfg., exemestane / Generic mfg.
New P2 trial, Metastases: Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 30, 2013
P2, N=35, Not yet recruiting, Sponsor: Organisation for Oncology and Translational Research
- veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Enrollment open, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - Dec 30, 2013
P2, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | temozolomide / Generic mfg., everolimus / Generic mfg.
New P2 trial: Everolimus With and Without Temozolomide in Adult Low Grade Glioma (clinicaltrials.gov) - Dec 26, 2013
P2, N=159, Not yet recruiting, Sponsor: University of California, San Francisco
- everolimus / Generic mfg., exemestane / Generic mfg.
Combination therapy, Metastases: Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer (clinicaltrials.gov) - Dec 26, 2013
P=N/A, N=50, Recruiting, Sponsor: Novartis Healthcare A/S
- ||||| everolimus / Generic mfg.
New P4 trial, Combination therapy: PROTECT: Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients (clinicaltrials.gov) - Dec 22, 2013
P4, N=234, Recruiting, Sponsor: Seoul St. Mary's Hospital
- everolimus / Generic mfg.
New P2 trial: Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. (clinicaltrials.gov) - Dec 19, 2013
P2, N=3, Recruiting, Sponsor: Novartis Pharmaceuticals
- | New P2 trial, Surgery, Metastases: Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (clinicaltrials.gov) - Dec 17, 2013
P2, N=66, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- Enrollment closed: Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=12, Active, not recruiting, Sponsor: Seattle Children's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma (clinicaltrials.gov) - Dec 16, 2013
P2, N=3, Terminated, Sponsor: Yale University
Not yet recruiting --> Active, not recruiting N=30 --> 3
- |||| Simulect (basiliximab) / Novartis
Clinical: TRANSFORMt: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (clinicaltrials.gov) - Dec 15, 2013
P4, N=2040, Recruiting, Sponsor: Novartis Pharmaceuticals
N=30 --> 3 Not yet recruiting --> Recruiting
- Sutent (sunitinib) / Pfizer, Nexavar (sorafenib) / Bayer, Amgen
Clinical: A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (clinicaltrials.gov) - Dec 15, 2013
P=N/A, N=50, Recruiting, Sponsor: Sun Yat-sen University
- ||| Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Dec 10, 2013
P2, N=108, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Enrollment closed: CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial (clinicaltrials.gov) - Dec 10, 2013
P3, N=175, Active, not recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting Terminated --> Active, not recruiting
- | everolimus / Generic mfg.
New P2 trial: CHONRAD: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (clinicaltrials.gov) - Dec 9, 2013
P2, N=57, Not yet recruiting, Sponsor: Centre Leon Berard
- Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Trial termination, Combination therapy, Metastases: A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 8, 2013
P1, N=11, Terminated, Sponsor: Hoffmann-La Roche
Terminated --> Active, not recruiting Completed --> Terminated
- dactolisib (RTB101) / Adicet Bio
Enrollment change, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Dec 5, 2013
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated N=73 --> 46
- dactolisib (RTB101) / Adicet Bio
Enrollment closed, Combination therapy, Metastases: Dose Finding Study of RAD001 (Everolimus, Afinitor (clinicaltrials.gov) - Dec 3, 2013
P1, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=73 --> 46 Suspended --> Active, not recruiting
- | Campath (alemtuzumab) / Sanofi
Enrollment closed: Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Dec 3, 2013
P1/2, N=44, Active, not recruiting, Sponsor: Mayo Clinic
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: ASPEN: Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Dec 2, 2013
P2, N=108, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change, Combination therapy, Metastases: COOPERATE-1: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Dec 1, 2013
P1, N=36, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=60 --> 36
- | everolimus / Generic mfg.
Enrollment open: UNIRAD: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy (clinicaltrials.gov) - Dec 1, 2013
P3, N=1984, Recruiting, Sponsor: UNICANCER
N=60 --> 36 Not yet recruiting --> Recruiting
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment closed, Combination therapy, Metastases: COOPERATE-1: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Dec 1, 2013
P1, N=36, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
New P2 trial: Everolimus Post Orthotopic Liver Transplant (clinicaltrials.gov) - Nov 28, 2013
P2, N=50, Recruiting, Sponsor: Tomoaki Kato
- | everolimus / Generic mfg.
New P2 trial: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - Nov 26, 2013
P2, N=25, Recruiting, Sponsor: Baylor College of Medicine
- vistusertib (AZD2014) / AstraZeneca
New P2 trial, Metastases: ZEBRA: An Open Label Randomized Phase II Study Comparing Azd2014 Versus Everolimus In Patients With Advanced Metastatic Renal Cancer And Progression On VEGF Targeted Therapy (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Recruiting, Sponsor: The Leeds Teaching Hospitals NHS Trust
- everolimus / Generic mfg.
Enrollment open: Everolimus Post Orthotopic Liver Transplant (clinicaltrials.gov) - Nov 24, 2013
P2, N=50, Recruiting, Sponsor: Tomoaki Kato
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
P2 data, Enrollment change: Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) (clinicaltrials.gov) - Nov 20, 2013
P2, N=30, Completed, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Not yet recruiting --> Recruiting N=25 --> 30
- everolimus / Generic mfg.
Trial completion, P2 data: Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) (clinicaltrials.gov) - Nov 20, 2013
P2, N=30, Completed, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
N=25 --> 30 Active, not recruiting --> Completed
- | letrozole / Generic mfg., everolimus / Generic mfg.
Biomarker, New P2 trial, IO biomarker, Metastases: A pilot, phase II, unblinded, single-arm study to evaluate how biomarkers of hormonal resistance work against treatment with everolimus plus letrozol in first line treatment of postmenopausal women with hormone positive metastatic or locallyadvanced breast cancer Estudio piloto de fase II, no enmascarado y con un solo brazo de tratamiento para evaluar como actuan los biomarcadores de resistencia hormonal frente al tratamiento con everolimus y letrozol en primera l (EUDRACT) - Nov 11, 2013
P2, N=53, Ongoing, Sponsor: Novartis Farmac
- everolimus / Generic mfg.
Clinical: Prediction of Everolimus-induced Interstitial Lung Disease (clinicaltrials.gov) - Nov 5, 2013
P=N/A, N=100, Not yet recruiting, Sponsor: Radboud University
- |||| everolimus / Generic mfg.
Enrollment open: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children (clinicaltrials.gov) - Oct 15, 2013
P2, N=65, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Simulect (basiliximab) / Novartis
Enrollment closed: Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program (clinicaltrials.gov) - Oct 15, 2013
P4, N=250, Active, not recruiting, Sponsor: Novartis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Enrollment change: Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (clinicaltrials.gov) - Oct 10, 2013
P3, N=184, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting N=500 --> 184
- everolimus / Generic mfg., erlotinib / Generic mfg.
Enrollment change: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (clinicaltrials.gov) - Oct 10, 2013
P2, N=17, Active, not recruiting, Sponsor: University of California, San Francisco
N=500 --> 184 N=44 --> 17
- | everolimus / Generic mfg.
New P2 trial, Metastases: Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study (clinicaltrials.gov) - Oct 9, 2013
P2, N=60, Active, not recruiting, Sponsor: Beijing Cancer Hospital